This site is now managed by the Commonwealth Department of Health and Aged Care. 

Australian Clinical Trials

Clinical Trial Details

Analysing compliance with Calcium and Vitamin D supplementations in patients receiving bone resorptive agents.

Print record Print record
Trial Information

Broad Health Condition Cancer

Specific Health ConditionBone
Other cancer types

Trial Focus

Recruitment Details

Recruitment status

Recruitment State

Icon Cancer Care South Brisbane - South Brisbane
Icon Cancer Care Wesley - Auchenflower
Icon Cancer Care Southport - Southport
Icon Cancer Care Chermside - Chermside

4101 - South Brisbane
4066 - Auchenflower
4215 - Southport
4032 - Chermside

Anticipated date of first participant enrolment3/05/2021

Anticipated date of last participant enrolment1/01/2024

Phase of TrialNot Applicable

Has the study received ethics approval?Further information iconApproved

Trial summary

This observational study will examine rates of compliance with calcium and vitamin D doses prescribed to cancer patients who may benefit from taking these supplements due to the type of cancer treatment drugs they have been given.

Who is it for?
You may be eligible for this study if you are 18 or older, you are receiving cancer treatment(s) including Denosumab, Pamidronate or Zoledronic acid and you are attending one of the Icon Cancer Centres in Queensland for treatment.

Study details
All enrolled participants will be asked to complete a survey that includes questions about their current cancer treatment, and whether they have been prescribed calcium and vitamin D in addition to their cancer treatment. It is expected that the survey will take approximately 15 minutes to complete, and participants will be asked to complete this during a scheduled clinic visit, therefore additional study visits are not required.

It is hoped this research will determine the current rate of calcium and vitamin D dose compliance in patients whose cancer treatment may have a negative impact on their bone health. It is hoped this study will also identify barriers that may make it difficult for patients to maintain their calcium and vitamin D doses and will then be able to make adjustments to address these barriers.


Key inclusion criteria

Patients over the age of 18 treated at Icon Cancer Centre sites where Denosumab, Pamidronate or Zoledronic acid has been prescribed between August 2021 and recruitment period of 24 months in total  or until goal participant numbers have been reached. 

Minimum age18 Years

GenderBoth males and females

Can Healthy volunteers participate? No

Key exclusion criteria

Patients with hyperglycemia of malignancy; 
Patients with history of osteoporosis.
Patients participating in other clinical trials 
Contact details and further information

Sponsor Primary Sponsor Type: Charities/Societies/Foundations
Primary Sponsor Name: Icon Cancer Foundation
Primary Sponsor Address: Level 1 / 22 Cordellia street, South Brisbane, QLD 4101
Primary Sponsor Country: Australia

Trial websiteNot applicable

Trial IDACTRN12621000383864

Contact person for information and recruitmentMrs
Ashleigh Smith
Icon Cancer Centre Chermside - Chermside Medical Complex, 1/956 Gympie Road, Chermside QLD 4032
+61 7 3737 4500
07 3737 4801

Email contact Further information